Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 2,048.74 ($27.77) and traded as high as GBX 2,144 ($29.06). Hikma Pharmaceuticals shares last traded at GBX 2,096 ($28.41), with a volume of 539,987 shares traded.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. reissued an "overweight" rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th. Berenberg Bank reiterated a "buy" rating and set a GBX 2,560 ($34.70) price objective on shares of Hikma Pharmaceuticals in a report on Monday, March 10th.
Get Our Latest Research Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Price Performance
The company has a market capitalization of £5.92 billion, a PE ratio of 20.94, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The firm has a fifty day simple moving average of GBX 1,988.97 and a 200 day simple moving average of GBX 2,048.99.
Insiders Place Their Bets
In other news, insider Said Darwazah sold 13,863 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of GBX 2,138 ($28.98), for a total value of £296,390.94 ($401,777.06). Also, insider Victoria Hull sold 2,777 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of GBX 1,800 ($24.40), for a total transaction of £49,986 ($67,759.25). 30.54% of the stock is owned by company insiders.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Read More
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
